Table 12.
Change in glycosylated haemoglobin in individual studies
| Study |
Glycosylated haemoglobin (%) |
P value | P value between groups | ||
| Group | Baseline | Study completion | |||
| Kuchay et al[11] | Empagliflozin | 9.0 (1.0) | 7.2 (0.6) | < 0.001 | 0.88 |
| Control | 9.1 (1.4) | 7.1 (0.9) | < 0.0001 | ||
| Ito et al[12] | Ipragliflozin | 8.5 (1.5) | 7.6 (1.0) | < 0.05 | 0.522 |
| Pioglitazone | 8.3 (1.4) | 7.1 (0.9) | < 0.05 | ||
| Shibuya et al[13] | Luseogliflozin | 7.8 (7.2, 7.9) | 6.5 (6.4, 7.0) | 0.002 | 0.023 |
| Metformin | 7.4 (6.9, 7.7) | 7.3 (6.7, 7.6) | 0.362 | ||
| Eriksson et al[14] | Placebo | 7.4 (0.8) | -0.1 (0.4)1 | - | - |
| Omega-3 CA | 7.4 (0.7) | +0.1 (0.4)1 | - | Non-significant2 | |
| Dapagliflozin | 7.4 (0.6) | -0.6 (0.7)1 | - | < 0.052 | |
| O + D | 7.5 (0.8) | -0.5 (0.5)1 | - | Non-significant2 | |
| Ohki et al[15] | Ipragliflozin | 8.4 (7.8-8.9) | 7.6 (6.9-8.2) | < 0.01 | - |
| Seko et al[16] | SGLT-2 inhibitor | 6.7 (0.1) | 6.5 (0.1) | 0.055 | Non-significant |
| Sitagliptin | 7.0 (0.3) | 6.9 (0.3) | 0.331 | ||
| Sumida et al[18] | Luseogliflozin | 7.3 (0.7) | 7.0 (0.7) | 0.002 | - |
1
Change from baseline.
2
Compared to placebo.
CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.